Evidence map›Paper›PMID 39929309›Full record

ArticleJournal of the American Academy of Dermatology2025

Frequency and timing of multiple skin cancer development in five cohorts.

Lee Wheless, Kai-Ping Liao, Siwei Zheng, Yao Li, Lydia Yao, Yaomin Xu, Christopher Madden, Jacqueline Ike, Isabelle T Smith, Dominique Mosley and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Academy of Dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Lee WhelessTennessee Valley Healthcare System VA Medical Center, Nashville, Tennessee; Division of Epidemiology Vanderbilt University Medical Center, Vanderbilt University Medical Center Department of Medicine, Nashville, Tennessee; Department of Dermatology, Nashville, Tennessee. Electronic address: lee.e.wheless@vumc.org.
Kai-Ping LiaoDepartment of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, Texas.
Siwei ZhengDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
Yao LiDepartment of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, Texas.
Lydia YaoDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
Yaomin XuDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
Christopher MaddenState University of New York Downstate College of Medicine, Brooklyn, New York.
Jacqueline IkeMeharry Medical College, Nashville, Tennessee.
Isabelle T SmithVanderbilt University, Nashville, Tennessee.
Dominique MosleyVanderbilt University School of Medicine, Nashville, Tennessee.
Sarah GrossarthQuillen College of Medicine, East Tennessee State University, Johnson City, Tennessee.
Rebecca I HartmanVA Boston Healthcare System, Boston, Massachusetts; Brigham and Women's Hospital Department of Dermatology, Boston, Massachusetts.
Otis WilsonTennessee Valley Healthcare System VA Medical Center, Nashville, Tennessee.
Adriana HungTennessee Valley Healthcare System VA Medical Center, Nashville, Tennessee; Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Mackenzie R WehnerDepartment of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Skin Cancer Risks and Risk Prediction in Patients with Actinic KeratosisK08CA263298 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Mackenzie Rachel Wehner · 2022 to 2026
$1.3M
CSRD VA I01 CX001897CSRD VA IK2 CX002452CSRD VA IK2 CX002531NCATS NIH HHS UL1 TR000445NCI NIH HHS K08 CA263298NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundMany patients will develop more than one skin cancer; however, most research to date has examined only case status.

objectiveDescribe the frequency and timing of the treatment of multiple skin cancers in individual patients over time.

methodsWe conducted a longitudinal claims and electronic health record-based cohort study to examine the frequency of skin cancer multiplicity. We used a validated phenotype for counting individual skin cancers.

resultsOur combined cohort included 5,508,374 patients and 13,102,123 total skin cancers treated. Forty-three percent of patients treated for skin cancer were treated for more than one skin cancer, most within 2 years of the initial skin cancer. A subset of 3% of patients were treated for 10 or more skin cancers and contributed 22% of all skin cancers treated in the combined cohort. LIMITATIONS: High-quality data on skin cancer types were not available. Databases and health records are not designed to capture skin cancer multiplicity well.

conclusionsNearly half of patients treated for skin cancer will develop at least one more. Better data formatting will allow for improved granularity in identifying individuals at high risk for multiple skin cancers and those unlikely to benefit from continued annual surveillance.

Indexed as

Neoplasms, Multiple PrimarySkin NeoplasmsAdultAgedAged, 80 and overBasal Cell CarcinomaCohort StudiesElectronic Health RecordsFemaleHumansLongitudinal StudiesMaleMelanomaMiddle AgedTime Factorscohort studyepidemiologyskin cancer

Identifiers

PMID39929309
PMCPMC12101941

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.